Preventing contrast-induced nephropathy with fenoldopam.

Hunter, D W; Chamsuddin, A; Bjarnason, H; Kowalik, K

Hunter, D W; Chamsuddin, A; Bjarnason, H; Kowalik, K.

Affiliation

Hunter DW; Department of Radiology, MMC 292, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

Tech Vasc Interv Radiol ; 4(1): 53-6, 2001 Mar.

Article in En | MEDLINE | ID: mdl-11981789

Subject(s)

Contrast Media/adverse effects; Dopamine Agonists/therapeutic use; Fenoldopam/therapeutic use; Kidney Diseases/chemically induced; Kidney Diseases/prevention & control; Animals; Blood Pressure/drug effects; Contrast Media/standards; Dopamine Agonists/standards; Dose-Response Relationship, Drug; Fenoldopam/standards; Humans; Kidney/blood supply; Kidney/drug effects; Regional Blood Flow/drug effects; Risk Factors; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Resistance/drug effects; Vasodilator Agents/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Fenoldopam / Dopamine Agonists / Contrast Media / Kidney Diseases Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Animals / Humans Country/Region as subject: America do norte Language: En Journal: Tech Vasc Interv Radiol Journal subject: ANGIOLOGIA / RADIOLOGIA Year: 2001 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links